Byetta Tracker App
Track Exenatide Twice-Daily Doses and Meal Timing in Shotlee
Byetta (exenatide 5 mcg or 10 mcg twice daily) was the first GLP-1 receptor agonist approved by the FDA in April 2005 — proving the entire GLP-1 drug class concept for type 2 diabetes. While largely superseded by weekly GLP-1 agents, Byetta remains in use and requires careful meal-timing adherence. Inject within 60 minutes before each of your two main meals. Track every dose and meal window in Shotlee.
What Is Byetta and Why Is It Historically Significant?
Byetta (exenatide) is based on exendin-4, a 39-amino acid peptide originally isolated from the venom of the Gila monster lizard (Heloderma suspectum). Exendin-4 has 53% sequence homology with human GLP-1 but resists DPP-4 degradation — giving it a 2.4-hour half-life vs the 2-minute half-life of native GLP-1. This was the breakthrough that made a GLP-1 drug viable for the first time.
Byetta was approved by the FDA on April 28, 2005 as the first GLP-1 receptor agonist — launching a drug class that now includes semaglutide, tirzepatide, and retatrutide. Its short half-life requires twice-daily dosing with meals. While weekly agents have replaced it for most new patients, Byetta continues to be prescribed where cost and formulary access favour it, and it established the clinical evidence base for the entire GLP-1 class.
Byetta Dose Schedule
Starting dose. Inject within 60 min before breakfast and before dinner (or your two main meals). Space doses at least 6 hours apart.
Full dose after 1 month if 5 mcg is tolerated. Most clinical trial data is based on the 10 mcg twice-daily dose.
Byetta Injection Timing — 4 Rules
Exenatide Clinical Data
What to Track in Shotlee
Twice-daily meal-timed injections require precise logging. Shotlee helps you build the consistent record Byetta demands.
Protocol FAQs
Yes, though less commonly. Byetta remains prescribed in some markets due to cost advantages, formulary coverage, and for patients who have established stable control on it. For new starts, weekly GLP-1 agents (Ozempic, Trulicity, Bydureon) are generally preferred due to convenience and equal or greater efficacy.
Ozempic (semaglutide 0.5–2 mg weekly) substantially outperforms Byetta on both HbA1c reduction and weight loss, requires injection only once per week, and has demonstrated cardiovascular mortality benefit. Byetta requires twice-daily meal-timed injections with lower HbA1c efficacy. For most patients, Ozempic is the clinically superior option if accessible.
Injecting Byetta after eating significantly increases nausea and reduces its postprandial glucose-lowering effect. The meal-timing mechanism of exenatide depends on GLP-1 receptor stimulation being active before and during gastric emptying. Inject within 60 minutes before your meal, not after.
Byetta alone (without sulphonylurea or insulin) rarely causes hypoglycaemia because it has a glucose-dependent mechanism. Risk increases when combined with sulphonylurea (glimepiride, glipizide) or insulin. Log your glucose readings in Shotlee when combining with these agents.
Byetta, approved in 2005, was the first GLP-1 receptor agonist in clinical use — the founding drug of a class that now includes semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and retatrutide. Without Byetta proving the concept clinically, the current GLP-1 revolution might have been delayed by years.
Track Your Byetta Protocol in Shotlee
Log twice-daily doses with meal timing, HbA1c, and side effects — all free in Shotlee.